Navidea Biopharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
– Chief Business Officer to Provide Business and Development Program Updates –
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents, today announced that Dr. Thomas Tulip, Executive Vice President and Chief Business Officer, will participate at the Jeffries 2012 Global Healthcare Conference on June 4-7 at the Grand Hyatt in New York City. Dr. Tulip will provide an update of the Company and its development programs on Wednesday, June 6, 2012 at 4:30 PM EDT.
Investors and the public are invited to listen to a live webcast of Dr. Tulip’s presentation at http://wsw.com/webcast/jeff68/navb/. Following the conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Brent Larson, 614-822-2330
Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released May 30, 2012